Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped The study closed temporarily in February 2012 pending analysis of samples collected. In October, 2012, Celgene requested closure of the study.

Conditions

Follicular Lymphoma
Marginal Zone Lymphoma

Interventions

DRUG: azacitidine
DRUG: lenalidomide

Sponsor

Duke University

Collaborators

[object Object]